WO2000040269A3 - Pharmaceutical compositions for treatment of diseased tissues - Google Patents
Pharmaceutical compositions for treatment of diseased tissues Download PDFInfo
- Publication number
- WO2000040269A3 WO2000040269A3 PCT/US2000/000191 US0000191W WO0040269A3 WO 2000040269 A3 WO2000040269 A3 WO 2000040269A3 US 0000191 W US0000191 W US 0000191W WO 0040269 A3 WO0040269 A3 WO 0040269A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunostimulant
- treatment
- cytotoxic
- composition
- diseased cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU34694/00A AU3469400A (en) | 1999-01-05 | 2000-01-05 | Pharmaceutical compositions for treatment of diseased tissues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11490699P | 1999-01-05 | 1999-01-05 | |
US60/114,906 | 1999-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000040269A2 WO2000040269A2 (en) | 2000-07-13 |
WO2000040269A3 true WO2000040269A3 (en) | 2000-11-30 |
Family
ID=22358161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/000191 WO2000040269A2 (en) | 1999-01-05 | 2000-01-05 | Pharmaceutical compositions for treatment of diseased tissues |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3469400A (en) |
WO (1) | WO2000040269A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
DE19957342A1 (en) * | 1999-11-29 | 2001-05-31 | Gruenenthal Gmbh | Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine |
WO2002069929A1 (en) * | 2001-03-06 | 2002-09-12 | Udo Dunzendorfer | Trifunctional systems for chronic illnesses |
US20020128258A1 (en) * | 2001-03-09 | 2002-09-12 | Jean-Pierre Robin | Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
EP1538907A4 (en) * | 2002-07-02 | 2008-12-24 | Southern Res Inst | Inhibitors of ftsz and uses thereof |
JP2006524632A (en) * | 2002-12-09 | 2006-11-02 | アメリカン バイオサイエンス、インコーポレイテッド | Composition and method of drug delivery |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
WO2007100382A2 (en) | 2005-10-27 | 2007-09-07 | Bernstein Lawrence R | Orally administrable gallium compositions and method of use |
WO2008058210A2 (en) | 2006-11-09 | 2008-05-15 | Bernstein Lawrence R | Local administration of gallium compositions to treat pain |
KR100923884B1 (en) * | 2007-12-11 | 2009-10-28 | 주식회사 알앤엘바이오 | Method for Preparing Alnus japonica Bark or Stem Extracts Having High Anti-Influenza Viral activity |
CN102070481A (en) * | 2009-06-11 | 2011-05-25 | 辽宁利锋科技开发有限公司 | Medicine tromantadine with adamantane structure, anti-tumor application of derivates and analogs thereof having new indications |
MY163296A (en) | 2011-08-30 | 2017-09-15 | Astex Pharmaceuticals Inc | Drug formulations |
CN106163542A (en) * | 2014-02-05 | 2016-11-23 | 雷波内制药有限公司 | For promoting the compositions of skin ulcer and wound healing |
US9592188B2 (en) | 2014-05-22 | 2017-03-14 | Yansong Liu | Method of treating or reducing the severity of dermatological conditions |
US10576109B2 (en) * | 2014-07-16 | 2020-03-03 | Depofarma S.P.A. | Propionibacterium acnes and granulosum parietal fraction having immunomodulating action |
US10105415B2 (en) | 2014-07-24 | 2018-10-23 | Reponex Pharmaceuticals A/S | Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease |
JP6713148B2 (en) * | 2014-08-07 | 2020-06-24 | レポネックス・ファーマシューティカルズ・エー/エス | Composition for the treatment of peritonitis |
MX2018000016A (en) | 2015-07-02 | 2019-01-31 | Otsuka Pharma Co Ltd | Lyophilized pharmaceutical compositions. |
EP3661522A2 (en) | 2017-08-03 | 2020-06-10 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
NL2031966B1 (en) * | 2022-05-23 | 2023-11-28 | Pleco Therapeutics B V | Chelating agents for use in cancer therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988000832A1 (en) * | 1986-07-30 | 1988-02-11 | Immunex Corporation | Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor |
US5476659A (en) * | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
-
2000
- 2000-01-05 WO PCT/US2000/000191 patent/WO2000040269A2/en active Application Filing
- 2000-01-05 AU AU34694/00A patent/AU3469400A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476659A (en) * | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
WO1988000832A1 (en) * | 1986-07-30 | 1988-02-11 | Immunex Corporation | Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor |
Non-Patent Citations (3)
Title |
---|
DURIE B. G. M., ET AL.: "High risk thyroid cancer prolonged survival with early multi modality therapy", CANCER CLIN. TRIALS, vol. 4, no. 1, 1981, pages 67 - 74, XP002146549 * |
NISHIDA T., ET AL.: "Therapeutic synergism in combination therapy of cis-diamminedichloroplatinum and a bacterial pyrogen on a transplantable ovarian cancer", RECENT ADV. CHEMOTHER.,PROC. INT. CONGR. CHEMOTHER., 14TH, vol. anticancer sect.1, 1985, pages 446 - 447, XP000918402 * |
ONYEJI, CYPRIAN O., ET AL.: "Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage coloony-stimulating factor against intromacrophage Mycobacterium avium-Mycobacterium intracellulare", J. INFECT. DIS., vol. 172, no. 3, 1995, pages 810 - 816, XP000918322 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
US9308180B2 (en) | 2005-08-31 | 2016-04-12 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
Also Published As
Publication number | Publication date |
---|---|
AU3469400A (en) | 2000-07-24 |
WO2000040269A2 (en) | 2000-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000040269A3 (en) | Pharmaceutical compositions for treatment of diseased tissues | |
JP6047207B2 (en) | Method and material for forming site-activated complex of biomolecule | |
IL133253A0 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
WO2005000245A3 (en) | Compositions and methods for increasing telomerase activity | |
DE69030880D1 (en) | Composition for stimulating the immune system | |
WO2006040076A2 (en) | Vaccination adjuvants pam3cys, poly(i:c), imiquimod, loxoribine, r-848 and cpg-dna together with mhc i or mhc ii epitopes | |
GR1002451B (en) | Anti-inflamatory compositions containing herbal-based active ingredients, methods of preparing same and uses of same for medical and veterinary purposes. | |
WO2006068759A3 (en) | Liposomes containing phytochemical agents and methods for making and using same | |
CN100512808C (en) | Externally applied compound amino acid prepn for promoting wound healing and its preparation process and application thereof | |
CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
Cui et al. | How microalgae is effective in oxygen deficiency aggravated diseases? A comprehensive review of literature | |
CN107427561A (en) | Skin wound therapeutic combination | |
DE60111637D1 (en) | BIOMATERIAL IN THE FORM OF MICROPARTICLES OF HYALURONIC SUCTION FOR MEDICAL USE | |
US20220362400A1 (en) | Pivoting electrodynamic composition and medicament | |
AU5643299A (en) | Humic acid and its use in the treatment of various conditions | |
CN105085647A (en) | Natural peptide Pb-CATH2 having anti-infection and antioxidant functions as well as gene and application of peptide | |
CN103816110A (en) | Preparation method of drug transdermal absorbent promoting fracture healing | |
KR20040076092A (en) | Methods for treating acne using ALA with cationic liposome | |
US20230149496A1 (en) | Blocking a pathogen from expressing a virulence factor | |
RU2228763C1 (en) | Method for treating the cases of purulent wounds | |
KR101922488B1 (en) | A composition for treating and preventing hair loss containing pozzolan, Sappan wood extract and siegesbockia herb extract | |
Barnes et al. | Hormone Influence on the Thiol Content of Hevea brasiliensis Latex | |
JP2002145791A (en) | Anti-inflammatory composition | |
EP0753309A2 (en) | Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases | |
RU2070411C1 (en) | Antiviral medicinal preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: COMMUNICATION PURSUANT TO RULE 85A(1)EPC |
|
122 | Ep: pct application non-entry in european phase |